The impact of the intensity of ovarian stimulation on embryo quality in predicted suboptimal responders. A randomized controlled trial.
EU CTIS ID: 2024-514322-23-00
What this study is testing
To compare the two stimulation groups of CC plus rFSH 150IU vs. 300IU regarding the number of GQB according to the Istanbul Consensus criteria
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- infertile patients undergoing ovarian stimulation for IVF
- AFC ≥ 5 and ≤ 10
- AMH ≤1.5 ng/ml (AMH result of up to one year will be valid)
- Age ≥ 35 years and ≤40 years
- BMI >18.5 and <25 kg/m2
- Willing to participate in the study
You likely can't join if
- AFC >10
- History of untreated autoimmune, endocrine or metabolic disorders
- Contraindication for hormonal treatment
- Preimplantation genetic diagnosis
- Severe male factor (sperm concentration <5M/mL)
- Recent history of severe disease requiring regular treatment (clinically significant concurrent medical condition that could compromise subject safety or interfered with the trial assessment and patients with any contraindication of being pregnant).
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.